Evaluate the Safety of Linaclotide in IBS-C Patients in China

CompletedOBSERVATIONAL
Enrollment

3,028

Participants

Timeline

Start Date

September 18, 2020

Primary Completion Date

February 3, 2023

Study Completion Date

February 3, 2023

Conditions
Irritable Bowel Syndrome-IBS
Trial Locations (29)

14030

Research Site, Baotou

100730

Research Site, Beijing

110001

Research Site, Shenyang

200025

Research Site, Shanghai

200433

Research Site, Shanghai

210008

Research Site, Nanjing

210029

Research Site, Nanjing

250012

Research Site, Jinan

256603

Research Site, Binzhou

300052

Research Site, Tianjin

330006

Research Site, Nanchang

430022

Research Site, Wuhan

450003

Research Site, Zhengzhou

510000

Research Site, Guangzhou

510655

Research Site, Guangzhou

518035

Research Site, Shenzhen

518110

Research Site, Guangzhou

610014

Research Site, Chengdu

614000

Research Site, Leshan

710000

Research Site, Xi'an

Unknown

Research Site, Beijing

Research Site, Chongqing

Research Site, Qingdao

Research Site, Shanghai

Research Site, Shenzhen

Research Site, Suzhou

Research Site, Ürümqi

Research Site, Wenzhou

030012

Research Site, Taiyuan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY